Bio Saga Blog - A Chronicle of Life Sciences & Informatics

Live Labcast: Enhance productivity with ease of use. Get the Most Out of Your Chromatography Data System with Agilent OpenLab CDSJoin us for live labcast on 30th March, 2020 from 3-4pm https://www.linkedin.com/posts/kameshwaran_labcast-session-get-the-most-out-of-your-activity-6648872465445552128-59f-

Data Integrity is your issue? How can I get tips on handling compliance queries during audits? Why data review process is so important ? Need answers to these questions? Join us for a live Labcast on Enhanced compliance, data integrity and tips on how to face audits on 23rd March from 3PM to 4PM IST https://lnkd.in/ffFZPTj https://www.linkedin.com/posts/kameshwaran_openlab-cds-enhanced-compliance-data-integrity-activity-6646664205363712000-a_LL

• Expands specialty diagnostics portfolio with attractive molecular diagnostics capabilities, including infectious disease testing • Complements leading life sciences offering with innovative sample preparation, assay and bioinformatics technologies  • Creates significant value and is expected to be immediately accretive to adjusted earnings per share after close WALTHAM, Mass. and VENLO, The Netherlands – March 3, 2020 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a leading global provider of molecular diagnostics and sample preparation technologies, today announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher’s proposal to acquire QIAGEN for €39 per share in cash. The offer price represents a premium of approximately 23% to the closing price of QIAGEN’s common stock on the Frankfurt Prime Standard on March